Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80 ml)

A total of 305 consecutive patients who were treated with the GreenLight HPS laser (American Medical Systems, Minnetonka, Minnesota, USA) at eight international centres since July 2006 were included. This subgroup analysis involved 63 patients in urinary retention, 70 patients on anticoagulants, and 52 patients with prostate volume ≥ 80 ml. Observation period was a maximum of 11 mo, and mean follow-up was 4.2 mo (SD: 4.5). For all patients, the changes in maximum flow rate (Qmax), postvoid residual urine, International Prostate Symptom Score, and prostate volume from baseline to follow-up were significant (p < 0.001). For those patients in retention prior to therapy, the only significant difference between groups with regard to change from baseline was for Qmax (p < 0.001). The use of anticoagulants had no significant effect on changes from baseline values. For those patients with glands ≥ 80 ml, the only significant difference in change from baseline was for prostate volume reduction (p < 0.001). The rate of complications reported was low in all groups. This study shows that the GreenLight HPS 120-W laser can be used effectively and safely in patients in retention, on anticoagulant therapy, and with large prostates.